Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase

Circulation Research

Volumn 107, Issue 7, 2010, Pages 877-887

  Jung, Saet Byel ^a,b,c   Kim, Cuk Seong ^a,b,c   Naqvi, Asma ^a,b   Yamamori, Tohru ^a,b   Mattagajasingh, Ilwola ^a,b   Hoffman, Timothy A ^a,b   Cole, Marsha P ^a   Kumar, Ajay ^a,b,c   Dericco, Jeremy S ^a,b   Jeon, Byeong Hwa ^d   Irani, Kaikobad ^a,b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c Vascular Medicine Institute   (United States)

^d Chungnam National University   (South Korea)

Author keywords

aspirin; calmodulin; endothelial NOS; HDAC3; lysine acetylation

Indexed keywords

ACETYLSALICYLIC ACID; CALMODULIN; CYCLOOXYGENASE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HISTONE DEACETYLASE 3; LYSINE; ANTITHROMBOCYTIC AGENT; HISTONE DEACETYLASE; NOS3 PROTEIN, HUMAN; NOS3 PROTEIN, MOUSE;

ACETYLATION; ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; ANIMAL; BOVINAE; C57BL MOUSE; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; KIDNEY; METABOLISM; MUTANT MOUSE STRAIN; PHYSIOLOGY; PROTEIN PROCESSING; UMBILICAL VEIN;

ACETYLATION; ANIMALS; ASPIRIN; CALMODULIN; CATTLE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HISTONE DEACETYLASES; HUMANS; KIDNEY; LYSINE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NITRIC OXIDE SYNTHASE TYPE III; PLATELET AGGREGATION INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; UMBILICAL VEINS;

EID: 77958002714     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.222968     Document Type: Article

References (51)

1. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-1218.
2. Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem. 1992;267:12387-12392.
3. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998; 97:716-720.
4. Magen E, Viskoper JR, Mishal J, Priluk R, London D, Yosefy C. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens. 2005;19: 667-673.
5. Bulckaen H, Prevost G, Boulanger E, Robitaille G, Roquet V, Gaxatte C, Garcon G, Corman B, Gosset P, Shirali P, Creusy C, Puisieux F. Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. Am J Physiol Heart Circ Physiol. 2008; 294:H1562-H1570.
6. Hermida RC, Ayala DE, Calvo C, Lopez JE. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol. 2005;46: 975-983.
7. Hermida RC, Ayala DE, Calvo C, Lopez JE, Fernandez JR, Mojon A, Dominguez MJ, Covelo M. Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients. Hypertension. 2003;41: 1259-1267. (Pubitemid 36706075)
8. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. Am J Hypertens. 2009;22:896-903.
9. Taubert D, Berkels R, Grosser N, Schroder H, Grundemann D, Schomig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol. 2004;143:159-165.
10. O'Kane P, Xie L, Liu Z, Queen L, Jackson G, Ji Y, Ferro A. Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res. 2009;83:123-130.
11. Bridges KR, Schmidt GJ, Jensen M, Cerami A, Bunn HF. The acetylation of hemoglobin by aspirin. In vitro and in vivo. J Clin Invest. 1975;56: 201-207.
12. Xu AS, Macdonald JM, Labotka RJ, London RE. NMR study of the sites of human hemoglobin acetylated by aspirin. Biochim Biophys Acta. 1999; 1432:333-349.
13. Macdonald JM, Haas AL, London RE. Novel mechanism of surface catalysis of protein adduct formation. NMR studies of the acetylation of ubiquitin. J Biol Chem. 2000;275:31908-31913.
14. Rosenkranz B, Frolich JC. Plasma concentrations and anti-platelet effects after low dose acetylsalicylic acid. Prostaglandins Leukot Med. 1985;19: 289-300.
15. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A. 1996;93:10417-10422.
16. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998; 95:13313-13318.
17. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995;2:637-643.
18. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399: 597-601.
19. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetro-poulos A, Sessa WC. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998;392:821-824.
20. Shilton BH, Walton DJ. Sites of glycation of human and horse liver alcohol dehydrogenase in vivo. J Biol Chem. 1991;266:5587-5592.
21. Michell BJ, Harris MB, Chen ZP, Ju H, Venema VJ, Blackstone MA, Huang W, Venema RC, Kemp BE. Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J Biol Chem. 2002;277:42344-42351.
22. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, DeRicco J, Kasuno K, Irani K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2007;104:14855-14860.
23. Salerno JC, Harris DE, Irizarry K, Patel B, Morales AJ, Smith SM, Martasek P, Roman LJ, Masters BS, Jones CL, Weissman BA, Lane P, Liu Q, Gross SS. An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase. J Biol Chem. 1997;272: 29769-29777.
24. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10:32-42.
25. Longworth MS, Laimins LA. Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene. 2006;25: 4495-4500.
26. Takami Y, Nakayama T. N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line. J Biol Chem. 2000;275:16191-16201.
27. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001;293: 1653-1657.
28. Gregoire S, Xiao L, Nie J, Zhang X, Xu M, Li J, Wong J, Seto E, Yang XJ. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol. 2007;27:1280-1295.
29. Thevenet L, Mejean C, Moniot B, Bonneaud N, Galeotti N, Aldrian-Herrada G, Poulat F, Berta P, Benkirane M, Boizet-Bonhoure B. Regulation of human SRY subcellular distribution by its acetylation/deacety-lation. EMBO J. 2004;23:3336-3345.
30. Inoue K, Kobayashi M, Yano K, Miura M, Izumi A, Mataki C, Doi T, Hamakubo T, Reid PC, Hume DA, Yoshida M, Aird WC, Kodama T, Minami T. Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression. Arterioscler Thromb Vasc Biol. 2006;26: 2652-2659.
31. Wang J, Mahmud SA, Bitterman PB, Huo Y, Slungaard A. Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem. 2007;282:28408-28418.
32. Skill NJ, Theodorakis NG, Wang YN, Wu JM, Redmond EM, Sitzmann JV. Role of cyclooxygenase isoforms in prostacyclin biosynthesis and murine prehepatic portal hypertension. Am J Physiol Gastrointest Liver Physiol. 2008;295:G953-G964.
33. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med. 2004;200:69-78.
34. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A. 1995;92:9475-9479.
35. Groeger AL, Cipollina C, Cole MP, Woodcock SR, Bonacci G, Rudolph TK, Rudolph V, Freeman BA, Schopfer FJ. Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat Chem Biol. 2010;6:433-441.
36. Li P, Kim SW, Li X, Datta S, Pond WG, Wu G. Dietary supplementation with cholesterol and docosahexaenoic acid increases the activity of the arginine-nitric oxide pathway in tissues of young pigs. Nitric Oxide. 2008;19:259-265.
37. Stebbins CL, Stice JP, Hart CM, Mbai FN, Knowlton AA. Effects of dietary decosahexaenoic acid (DHA) on eNOS in human coronary artery endothelial cells. J Cardiovasc Pharmacol Ther. 2008;13: 261-268.
38. Szerafin T, Erdei N, Fulop T, Pasztor ET, Edes I, Koller A, Bagi Z. Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ Res. 2006;99:e12-e17.
39. Kalinowski L, Dobrucki IT, Malinski T. Cicletanine stimulates nitric oxide release and scavenges superoxide in endothelial cells. J Cardiovasc Pharmacol. 2001;37:713-724. (Pubitemid 32480440)
40. Malinski T, Taha Z. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. 1992;358: 676-678.
41. Gan Y, Shen YH, Wang J, Wang X, Utama B, Wang J, Wang XL. Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase. J Biol Chem. 2005;280:16467-16475.
42. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, Zeiher AM, Dimmeler S. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothe-lial cell function in vasorelaxation and angiogenesis. Circ Res. 2002;91: 837-844.
43. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987; 2:1057-1058. (Pubitemid 17154788)
44. Luscher TF. Endothelium in the control of vascular tone and growth: role of local mediators and mechanical forces. Blood Press Suppl. 1994;1: 18-22.
45. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99:608-615.
46. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348: 883-890. (Pubitemid 36297996)
47. Liu P, Li S, Gan L, Kao TP, Huang H. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res. 2008;68: 10290-10299.
48. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281:13548-13558.
49. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and athero-thrombotic disease. J Am Coll Cardiol. 2005;46:986-993.
50. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today. 2005;10:197-204.
51. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003;9:3578-3588.